Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
about
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerWell-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastasesRadium-223 for the Management of Bone Metastases in Castration-Resistant Prostate CancerThe elements of life and medicinesBeyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone diseasePathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity studyBone metastasis in prostate cancer: emerging therapeutic strategies.The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases.
P2860
Q26823733-542FA404-88E5-474C-A7C4-AAA3DAA3121EQ27002591-CF944B59-57A8-4601-96D9-086A1020354BQ28073320-4FA6993B-0D74-466E-8BF7-EE5FF3C3CD4DQ28649323-C933A5CB-A289-4EC6-8E42-A541927B46DCQ35057029-17689901-E142-4CC5-BA2E-6DA765C81E41Q37100364-6687BC72-5E46-433A-A2A6-4AD68AC0C547Q37187646-B0AE2590-2A86-4532-8242-2DB5F1FB158EQ37299562-42176B45-A3DC-4E9A-8345-68FD074FCBD1Q37873719-0C2A6729-8BAA-4C14-B04C-49BE458BD247Q38001275-84311FB8-70D8-4888-A853-3CD8554FD5F9Q38297692-C0AC7F41-B25F-4ED7-8A26-323119FE04E1Q49908522-5BABB880-D3E3-4DC0-9930-8F4F255E0478Q55088758-257ED2E0-596E-47A0-BEED-87C5949A5A57
P2860
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Combined use of zoledronic aci ...... patients with bone metastases.
@en
Combined use of zoledronic aci ...... patients with bone metastases.
@nl
type
label
Combined use of zoledronic aci ...... patients with bone metastases.
@en
Combined use of zoledronic aci ...... patients with bone metastases.
@nl
prefLabel
Combined use of zoledronic aci ...... patients with bone metastases.
@en
Combined use of zoledronic aci ...... patients with bone metastases.
@nl
P2093
P2860
P1476
Combined use of zoledronic aci ...... patients with bone metastases.
@en
P2093
Amel Dahmane
Bernard A Zonnenberg
John M H de Klerk
Marnix G E H Lam
Peter P van Rijk
Wil H M Stevens
P2860
P2888
P304
P356
10.1007/S00259-007-0659-Z
P577
2007-12-22T00:00:00Z